SGLT2 inhibition, high-density lipoprotein, and kidney function: a mendelian randomization study
Abstract Background Sodium-glucose cotransporter 2 (SGLT2) inhibition is recognized for its evident renoprotective benefits in diabetic renal disease. Recent data suggest that SGLT2 inhibition also slows down kidney disease progression and reduces the risk of acute kidney injury, regardless of wheth...
Main Authors: | Zhijuan Wang, Jie Wei, Wenman Zhao, Rui Shi, Yuyu Zhu, Xunliang Li, Deguang Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-03-01
|
Series: | Lipids in Health and Disease |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12944-024-02072-6 |
Similar Items
-
SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
by: Jiang Li, et al.
Published: (2023-10-01) -
Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study
by: Wenqin Guo, et al.
Published: (2024-04-01) -
Low-density lipoprotein cholesterol and risk of hepatocellular carcinoma: a Mendelian randomization and mediation analysis
by: Jiali Cao, et al.
Published: (2023-07-01) -
The Causal Effect of Obesity on the Risk of 15 Autoimmune Diseases: A Mendelian Randomization Study
by: Xunliang Li, et al.
Published: (2023-10-01) -
Additive Effects of Genetic Interleukin‐6 Signaling Downregulation and Low‐Density Lipoprotein Cholesterol Lowering on Cardiovascular Disease: A 2×2 Factorial Mendelian Randomization Analysis
by: Marios K. Georgakis, et al.
Published: (2022-01-01)